What diseases does acalatinib/acalatinib mainly treat?

Acalabrutinib/Acalabrutinib (Acalabrutinib) is a new generation Bruton's tyrosine kinase (BTK) inhibitor that is widely used in the treatment of a variety of B-cell malignancies. The original intention of its research and development is to minimize the adverse reactions caused by previous generation BTK inhibitors such as ibrutinib on the basis of ensuring anti-tumor activity. The main indications of acotinib include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). It has been gradually approved in many countries and regions and has become one of the core targeted drugs for this type of disease.

The core of the drug's treatment lies in selectively inhibiting the BTK signaling pathway, which is a key node in B cell maturation and survival. In diseases such as CLL, the BTK pathway is often in an abnormally activated state, promoting continued proliferation of cancer cells and evading immune clearance. By precisely inhibiting this target, acotinib can block the survival signal of diseased B cells, thereby achieving effective tumor control. Compared with previous generation BTK inhibitors, acotinib has higher selectivity and lower inhibitory effect on other tyrosine kinases such as EGFR or ITK, so it has certain improvements in side effects such as arrhythmia and bleeding risk.

In addition, acotinib's ability to penetrate the central nervous system has also attracted research attention, especially in the treatment of rare centrally involved type B-cell lymphoma. It is worth noting that acotinib is often used as a single agent, but in some patients it can also be combined with anti-CD20 antibody drugs (such as obinutuzumab) to enhance the depth of treatment response. For elderly, frail, and multi-morbid patients, acotinib’s good tolerability and sustained efficacy make it an ideal long-term maintenance treatment option.

Overall, acotinib represents an important achievement in moving B cell targeted therapy towards higher selectivity and lower toxicity.

Reference materials:https://www.calquence.com/